Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q4 results saw “no surprises” to its pre-announcement, and more importantly, its Phase 3 study of solriamfetol in ADHD remain on track for Q1, the analyst tells investors in a research note. . As a DEA Schedule IV drug, if approved for ADHD, solriamfetol may be favored over other ADHD drugs such as Ritalin, Adderall, Vyvanse, etc, the firm adds.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $192 from $143 at RBC Capital
- Axsome Therapeutics price target raised to $153 from $133 at Needham
- Positive Outlook for Axsome Therapeutics Amid Key Developments and Growth Potential
- Promising Growth and Market Expansion Drive Buy Rating for Axsome Therapeutics
- Axsome Therapeutics price target raised to $195 from $135 at Guggenheim